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ABSTRACT:
p63 is a transcriptional factor belonging to p53 family of genes. Beside the 
role in cancer, partially shared with p53 and the other member p73, p63 also plays 
exclusive roles in development and homeostasis of ectodermal/epidermal-related 
organs. Here we show that p63 transcriptionally controls the expression of the matrix 
metallopeptidase 13 (MMP13). p63 binds a p53-like responsive element in the human 
promoter of MMP13, thus promoting the activation of its transcription. The catalytic 
activity of MMP13 is required in high invasion capacity of metastatic cancer cells, 
however, although p63 and MMP13 expression correlates in cancer patients, their 
co-expression does not predict cancer patient survival. Our results demonstrate that 
p63 directly controls MMP13 expression. 
INTRODUCTION
p63 is a p53-related transcriptional factor, which 
plays roles in development and cancer. Different promoter 
regions control the expression of two N-terminal isoforms, 
TAp63 and ΔNp63. The P1 promoter, located upstream 
of exon 1, controls expression of a transactivation 
domain (TA)-containing isoform (TAp63), whereas the 
P2 promoter controls, located in intron 3, promotes the 
expression of the N-terminal truncated isoform  (ΔNp63), 
which lacks the first TA domain. Alternative splicings at 
the 3’ region of p63 pre-mRNA generates three additional 
C-terminal isoforms, p63α (full length), p63β (lacking 
exon 13) and p63γ (lacking exons 11-14).
 In response to the DNA damage TAp63 can induce 
cell cycle arrest and apoptosis, partially overlapping 
function of the others p53 family members, p73[1-4] 
and p53 [5-10]. In addition, overlapping involvement 
of all three family members have also been described in 
metabolism of glutamine[11-15] and serine/glycine[16, 
17]. TAp63 has been detected at low levels in different 
tissues, especially following stress[18]. However, the 
predominant expression is confined in oocytes, where, in 
response to genotoxic insults, promotes the induction of 
BH3-only pro-apoptotic BCL-2 family members, PUMA 
[19-23] and NOXA[24-30]. Thus, TAp63 has been named 
the ‘guardian of the female germline’ [31, 32]. However, 
TAp63 controls also other cell cycle regulators and pro-
apoptotic genes, some of which shared with p53 and 
p73, including p21[33], Casp-1,2,3,4,5,8,9 [34-37], TNF, 
TNF-R1, TRAL-R1, -R2 [38-41]. TAp63 also plays a role 
in metastasis suppression, repressing TGF-β-mediated 
invasiveness. Mutant-p53 forms a ternary complex with 
Smad and p63 [42-46], antagonizing the p63 metastasis 
suppression function . Overall, the different N-terminal 
isoform functions, the tissue-specific expression and 
interaction with other paralogue genes p53 and p73 [47] 
arise high complexity to p63 function in cancer (for rev. 
see [48]). 
ΔNp63 is master regulator of epithelial development 
and differentiation. p63-/- (lacking all p63 isoforms) [49-
52] and ΔNp63-/- selective null-mice [53] present severe 
development abnormalities, including limb truncations, 
craniofacial malformations and the lack of an intact 
epidermis. Moreover, these animals are born without 
teeth, mammary glands, prostate or skin appendages – 
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structures that are highly dependent on proper epithelial-
mesenchymal interactions. ΔNp63 directly drives 
epidermal morphogenesis and preserves epidermal 
homeostasis, maintaining basal keratinocyte proliferative 
potential in adult normal epidermis [54, 55], through 
regulation of crucial transcriptional target genes[56-60] 
and microRNAs[61-63]. Recently, Flores group has 
revealed a role for ΔNp63 in the reprogram adult somatic 
cells into multipotent stem cells. They showed that 
ΔNp63-/- epidermal cells express a subset of markers 
present in embryonic stem cells and fibroblasts induced 
to pluripotency using Yamanaka factors [64]. p63 has also 
been proven to be involved in cutaneous wound healing 
[65], however still little is known about p63 targets genes 
during re-epithelialization. 
 Human matrix Metallopeptidase 13 (MMP13), 
also known as collagenase-3, is a proteolytic enzyme, 
identified in 1994 by Freij and colleagues [66]. The 
substrate specificity of MMP13 indicated that this 
protease exhibits high proteolytic activity toward fibrillar 
type I, II, and III collagens [67]. It plays crucial roles in 
physiological processes such as fetal bone development 
[68], skeletal development [69, 70], articular cartilage 
and synovial membrane functionality [71]. MMP13 is 
low expressed in proliferating keratinocytes, but highly 
induced at the leading edge of skin wound [72, 73]. Many 
factors can control keratinocyte migration [65, 74, 75], 
but the limiting process is the attachment of keratinocytes 
to fibrillar type I collagen and subsequent degradation of 
the collagen by collagenolytic MMPs [76-78]. MMP13 
overexpression indeed promotes keratinocyte migration, 
mediating degradation of the collagen and consequent cell 
detachment from the basal membrane. It has also been 
proved that MMP13 is involved in re-epithelialization 
in wound healing in mice [77]. However, other studies 
raised a debate on this issue, since MMP13-/- mice failed to 
demonstrate significant difference or showed acceleration 
of wound closure and re-epithelialization [79]. MMPs are 
generally considered important targets for human diseases 
where these enzymes have been found overexpressed and/
or where excessive collagen degradation is involved[80, 
81]. Pathological states associated to MMP13 upregulation 
are different type of cancers[82], osteoarthritis[83, 
84], and rheumatoid arthritis[85]. In human cancer 
upregulation of MMP13 contributes to metastasis onset 
[72]. The catalytic activity of MMP13 may play a role in 
the high invasion capacity of cancer cells. Degradation 
of basement membrane is thought to be an early and 
critical event influencing tumor invasion and metastasis. 
Thus, MMP13 represents a negative prognostic factor for 
different cancers [82, 86, 87]. Recently, our group has 
identified MMP13 as a direct transcriptional target of the 
p63 homologous, TAp73[88].
Here we describe MMP13 as target of p63. p63 
can indeed transcriptionally control the expression of 
MMP13 by binding its promoter gene and promoting its 
expression. This finding indicates a novel target gene of 
p63 that can help to elucidate p63 role in cancer and in the 
re-epithelialization process during wound healing.
RESULTS AND DISCUSSION
p63 promotes MMP13 expression
In a gene expression-profiling analysis on TAp63 
and ΔNp63 overexpressing cells performed by microarray 
approaches, we identified important subsets of genes, 
which potentially might be transcriptionally regulated by 
p63. Among the genes, whose expression was modulated 
by both TAp63 and ΔNp63 isoforms, we focused on 
MMP13. 
To validate the microarray data, we employed 
SaOs-2 Tet On cell lines, where expression of TAp63α 
or ΔNp63α can be induced by the tetracycline analog, 
doxycycline. Real time qPCR, performed in a time course 
analysis from 0h to 24h of doxycycline treatment, showed 
a significant induction of exogenous TAp63α and ΔNp63α 
and a consistent upregulation of the previously reported 
p63 transcriptional target, p21 (Fig. 1A,B). qPCR on 
the time course induction of both TAp63α and ΔNp63α 
SaOs-2 cell lines showed a time-dependent upregulation 
of MMP13, confirming the result of the microarray 
analysis (Fig. 1A,B). To confirm this regulation at protein 
level we performed western blot analysis on TAp63α and 
ΔNp63α SaOs-2 cell lines upon doxycycline treatment. 
Consistently, MMP13 protein levels were upregulated in 
time-dependent fashion, when HA-tagged TAp63α and 
ΔNp63α were induced (Fig. 1C,D). Notably, detectable 
levels of MMP13 were already observed in absence of p63 
overexpression (time 0h). Being all p53-family members 
undetectable in parental SaOs-2 cell line, this observation 
suggested that alternative mechanisms are also involved in 
transcriptional regulation at least of basal level of MMP13. 
Overall, our data suggest that p63 controls expression of 
MMP13. 
p63 directly binds human MMP13 promoter
To deeply investigate the mechanisms by which 
p63 controls MMP13 expression, we hypostasized that a 
direct binding of p63 on MMP13 gene promoter might 
be responsible of the transcriptional regulation of the 
gene. To screen MMP13 promoter sequence in order to 
identify p63 (p53-like) responsive elements (RE), we 
employed MatInspector Professional software [89]. We 
analyzed the first 1.6 Kb upstream the transcriptional 
start, searching for the p53-like consensus motifs (matrix 
V$P53F/P5301), which contained the core sequence 
CATC. The in silico analysis suggested that region 
between -345/-370 contained a putative consensus 
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Figure 1: p63 upregulates mRNA and protein levels of MMP13. (a,b)  mRNA expression of MMP13 was induced by both p63 
isoforms in a time-dependent manner. Levels of MMP13 and of the previously described p63 target gene, p21, were evaluated by real 
time qPCR following the TAp63α (a) and ΔNp63α (b) induction after 3, 6, 12, 24 hours (h) of 4μg/ml doxycycline (Doxy) treatment in 
SaOs-2 inducible cells. Relative expression of MMP13 and p21 was normalized using the housekeeping gene, TBP, and calculated as fold 
induction. Data represent mean ± SD of three different experiments. *, p < 0.01 (c,d) MMP13 protein induced by TAp63α (c) and ΔNp63α 
(d) at the same time indicated for qPCR. Western blot analysis was performed using the indicated antibodies. GAPDH or Actin were 
evaluated as control. The experiment is representative of three independent experiments. 
Figure 2: p63 directly binds and transactivates MMP13 promoter. (a) Schematic map of human MMP13 promoter region 
with the p53-like RE. The insert shows the sequence of p53 RE, located between -345 and -370 bp upstream of transcription-start site. (b) 
SaOs-2 cells were induced with 4μg/ml doxycycline for 24h. The sonicated chromatin was bound to ΔNp63α-HA and amplified by PCR 
with MMP13 primer that recognizes the p53-response element. ChIP on MDM2 promoter was performed as a positive control. Mouse IgG 
antibody was used as negative control of the ChIP procedure. (c) Both TAp63α and ΔNp63α isoforms transactivate MMP13 promoter at 
48h. The MMP13 promoter activity was evaluated after cotransfection with pcDNA vector, TAp63α ΔNp63αplasmids. The luciferase assay 
was performed after 48h and 72h of cotransfection in 293T cells and was normalized with Renilla luciferase vector. The graphs show a 
mean ± SD of three different experiments. **, p < 0.01; *, p < 0.05; (d) Western blot analysis on lysates from luciferase assay was performed 
as control of p63 protein overexpression. Actin was used as loading control.
Oncotarget1282www.impactjournals.com/oncotarget
sequence, which potentially might be bound by p63 (Fig. 
2A). To experimentally prove the direct binding of p63 
on this consensus sequences we designed a ChIP assay. 
To perform ChIP we used ΔNp63 SaOs-2 Tet On cells, 
where expression of ΔNp63 was induced for 24h by 
doxycycline. The immunoprecipitated chromatin was 
then subjected to a PCR designed to amplify the p53-
RE region included in the MMP13 promoter (Fig. 2A). 
PCR band was specifically detected only in the anti-HA 
immunoprecipitated chromatin, when compared with 
anti-IgG immunoprecipitated control chromatin. Notably, 
as p63 binding on MDM2 promoter region was already 
reported, PCR to detect p53 responsive element in MDM2 
promoter region was performed as positive control of 
the experimental procedure. Hence, our ChIP analysis 
demonstrated the physical interaction of p63 with the p53-
like RE in the MMP13 promoter, strongly suggesting that 
MMP13 might be a de novo transcriptional target gene of 
p63 (Fig. 2B).
p63 activates transcriptional regulation of 
MMP13 promoter
To elucidate whether the direct binding of p63 on 
MMP13 promoter was functional, the -1600 bp upstream 
the transcriptional start were inserted into luciferase 
reporter plasmid to evaluate the transcriptional ability 
of p63 on this genomic region (Fig. 2A). The promoter 
was then cotransfected into 293T cells together with HA-
tagged TAp63α or ΔNp63α or empty control vector. 48h 
after transfection, increased luciferase activity confirmed 
a significant transcriptional activation of MMP13 
promoter by both TAp63α and ΔNp63α (respectively 
2.3- and 1.5-fold increase). Consistently, after 72h of 
transfection similar trend was confirmed, although only 
TAp63α overexpressing cells provided a statistical 
significant increase (Fig. 2C). Notably, western blot 
analysis confirmed good transfection efficiency for both 
TAp63α and ΔNp63α at the two time points (Fig. 2D). 
These data demonstrate that p63 binding on the binding 
sequences located at -370/-345 from transcription-start 
site is functionally active to promote MMP13 expression. 
However, the qPCR results shown in figure 1, where 
p63-dependent upregulation of MMP13 showed up to 
7-fold increase, would suggest that, besides this p53-RE, 
additional consensus sequences might be involved in the 
transcriptional regulation of MMP13 by p63. 
p63 correlates with MMP13 expression in cancer 
patients
To confirm the existence and to assess the relevance 
of p63/MMP13 axis, we searched for expression 
correlation of these two genes in human cancer patient 
datasets. Breast cancer represents a heterogeneous group 
of diseases with different biological and morphological 
features, although strong efforts have been placed in 
identification of biomarkers of high-grade/metastatic forms 
of this disease[90-92], still much is expected to improve 
prognostic and predictive marker assessment. Melanoma 
is among the most aggressive cancer, with high incidence 
of metastasis and advanced stages progression [93-96]. 
Therefore to confirm p63/MMP13 relevance in cancer, we 
selected two cancer datasets: a breast carcinoma cohort 
[97] of 87 samples and a melanoma cohort, which included 
25 melanomas [98], 9 non-neoplastic nevus and 3 normal 
samples. Coexpression analysis showed direct association 
between p63 and MMP13 mRNA level in both the datasets 
analysed. The breast cancer dataset presented a correlation 
factor of 0.293, while the melanoma dataset of 0.298 (Fig. 
3A,B). These data confirm a coexpression and a direct 
correlation of p63 and MMP13 in human cancers. The 
melanoma dataset included normal and non-neoplastic 
specimens. Interestingly, a clear switch from high p63/
MMP13 expression to low p63/MMP13 occurred in the 
transition towards the malignant state of melanocytes (Fig. 
3B). To further investigate the function of p63/MMP13 
in cancer, we decided to analysed MMP13 ability to 
function as prognostic factor of human cancer. We used 
three different publicly available datasets of human 
cancer, which included patient survival information (lung 
adenocarcinoma GSE31210, breast cancer GSE2034, and 
liposarcoma GSE30929). Patient datasets were clustered 
according to the expression of MMP13 (high expressing, 
low expressing). Kaplan-Mayer curve for survival 
estimation showed that a high MMP13 expression was 
predictive of poor survival (Fig. 4A-C), suggesting that 
MMP13 plays an important role in cancer aggressiveness. 
In order to elucidate whether p63 functions as a controller 
of MMP13 expression in cancer, we evaluated the 
biological consequence of p63/MMP13 coexpression 
in cancer patients. We selected the datasets analyzed in 
figure 4 (lung adenocarcinoma GSE31210, breast cancer 
GSE2034, and liposarcoma GSE30929) and we split the 
samples in two cohorts. The first cohort included all the 
samples to maximize positive correlation between p63 and 
MMP13, while in the second cohort all the other samples 
were included  (Fig. 5). Thus, we clustered the dataset in 
two biological groups: one where p63/MMP13 axis was 
present (p63/MMP13 interaction), and second in which 
it was absent (p63/MMP13 NO interaction). Performing 
Kaplan-Mayer survival estimation the two cohorts did not 
show any significant difference in the survival expectation 
(Fig. 5). These data suggest that, although p63 is able to 
control MMP13 expression, it is very unlikely this axis 
plays any relevant role in cancer biology.    
CONCLUSION
p63 plays fundamental roles in development 
and homeostasis of the epidermis as well as in cancer. 
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Figure 3: p63 and MMP13 expression directly correlates in human breast and melanoma cancers. (a,b) Expression data 
from Oncomine website (www.oncomine.org). We used the following filters: gene ‘TP63’; Analysis Type: ‘Coexpression analysis’; Cancer 
Type: Breast (a) or Melanoma Cancer (b). The colour changes according to a weaker (blue) or higher (red) expression, passing by white, 
with fluctuating colour intensity. The reporters indicate probes used for the analysis. 
Figure 4: MMP13 expression is a negative prognostic marker in human cancers. (a-c) Three different human cancer datasets 
have been analysed: GSE31210 (Lung adenocarcinoma a), GSE2034 (Breast cancer b), GSE30929 (Liposarcoma c). The panels represent 
patient survival estimation of MMP13 high expressing compared to low expressing groups. 
Figure 5: p63/MMP13 correlation does not function as prognostic marker in cancer. Three different human cancer datasets 
have been analysed: lung adenocarcinoma GSE31210 (a), breast cancer GSE2034 (b), liposarcoma GSE30929 (c). (a-c) Left and central 
panels respectively represent p63 and MMP13 expression profiles in the cohorts 1 (p63/MMP13 Interaction) and cohorts 2 (p63/MMP13 
NO Interaction). Right panels represent patient survival estimation in the two groups.
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Here we have identified the matrix metallopeptidase 
13, MMP13, as direct transcriptional target of p63. A 
wide overlapping involvement of all p53-family occurs 
in the transcriptional regulation of MMP13. We have 
indeed recently demonstrated that MMP-13 is a direct 
downstream target of p73 [88]. In addition wt p53 and 
mutant p53 (mp53) exert opposite regulation on MMP13 
expression. Wt p53 represses MMP13, while mp53 
promotes MMP13 expression in wt p53 expressing 
cells[99]. This regulation is in line with pro-metastatic 
ability of mp53 (gain-of-function feature), however our 
data do not suggest a direct involvement of p63/MMP13 
axis in cancer progression. Our clinical analyses suggest 
that p63-dependent regulation of MMP13 has not direct 
impact on survival outcome of cancer patient. This 
observation tempts to speculate that MMP13 regulation by 
p63 may represent an important axis in epidermal wound 
healing and skin homeostasis. Being both available p63 
and MMP13 animal models, further investigations will 
clarify the relationship between these two genes in order 
to provide a deeper understanding of their the biological 
relevance of their interaction.  
MATERIALS AND METHODS
Cell cultures and Transfection
All cell lines were grown at 37°C in a humidified 
atmosphere of 5% CO
2
 in air. SaOs-2–Tet–On cells 
were maintained in RPMI, 10% (vol/vol) Tet-free FCS 
(Clontech), penicillin/streptomycin 1 unit/ml (Gibco) 
and 250mM L-glutamine (Gibco). A Tet-responsive 
transcriptional activator rtTA was used to obtain SaOs-2 
clones with the inducible expression of TAα and ΔNα p63 
isoforms (Tet–On system). 293T cells were maintained in 
RPMI, 10% (vol/vol)  FCS (Invitrogen) 250 mM sodium 
pyruvate (Gibco), penicillin/streptomycin 1 unit/ml 
(Gibco) and 250 mM L-glutamine (Gibco). 
Cell transfection and luciferase assay
293T cells were seeded 24h before the transfection 
at density of 1 x 105 in 12-well dishes. The day after, 
cells were co-transfected with 300ng/well of HA-tagged 
pGL3 vector or TAp63α and ΔNp63α plasmids, 100ng/
well MMP13 luciferase reporter plasmid and 2ng/well 
pRL-cytomegalovirus vector. Transfection was carried 
out by Effectene reagent (Qiagen) according to the 
manufacturer’s instructions. After 48h and 72h from the 
transfection, the luciferase activities of cellular extracts 
were detected using a Dual-Luciferase Reporter Assay 
System (Genecopoeia). Renilla luciferase activity was 
used to normalize the transfection efficiency. Light 
emission was measured over 5s using a luminometer (with 
Glomax 96 Microplate Luminometer, Promega (Madison, 
WI, USA)). 
Western Blotting
Proteins were extracted with RIPA buffer containing 
mixture inhibitors (Roche), followed by homogenization 
by using QIAshredder (Qiagen) and evaluation of 
concentration by using a Bradford dye-based assay 
(Bio-Rad). 50μg of total proteins were loaded on 10% 
SDS/PAGE and transferred to polyvinylidene difluoride 
membranes (Hybond; GE Healthcare), followed by 
immunoblotting with appropriate antibodies. The blots 
were then incubated with peroxidase linked secondary 
antibodies followed by enhanced-chemiluminescent 
detection using ECL kit (Amersham). Primary antibodies 
were used as followed: anti-HA 1 : 100  (Covance); anti-
MMP13 1:500 (Millipore); anti-actin and anti-GAPDH 1 
: 10.000 (Sigma-Aldrich).
RNA extraction and quantitative real-time PCR
After 4μg/ml doxycycline induction, total RNA 
was extracted from TAp63α and ΔNp63α SaOs-2 cells 
by using the RNeasy Mini Kit (Qiagen) and quantified 
by spectrophotometric analysis. Reverse transcription 
from 1μg of total RNA was performed using InPromII 
kit (Promega); 1/5 of cDNA obtained was used for 
real-time PCR. The primers used for the real-time PCR 
were: MMP13 +ATATGACTATGCGTGGCTGGAAC, 
_CCATGTGTCCCATTTGTGGTGTG; 
p21 +TGGGGATGTCCGTCAGAAC, _
GGCGTTTGGAGTGGTAGAAATC; TBP 
+TCAAACCCAGAATTGTTCTCCTTAT, _
CCTGAATCCCTTTAGAATAGGGTAGA. SYBR green 
ready mix (Applied Biosystems) was used to perform the 
real-time PCR. For the quantity normalization we used 
TBP as housekeeping gene; relative quantification of 
gene expression was analyzed according to the method 
of 2 -ΔΔCt reported in the User Bulletin no. 2 and the 
Relative Quantification software version 1.3 of Applied 
Biosystems.
Analysis of promoter region
Analysis of promoter region was performed 
using Math-Inspector Professional software and the 
TRANSFAC database on a region of 1600kb upstream 
of the transcription-start site of the human MMP13. The 
analysis highlighted a 25bp region containing a p53-like 
RE site. The MMP13 promoter plasmid was purchased 
from Genecopoeia (vector: pEZX-PG02).
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Chromatin immunoprecipitation assay 
After induction of ΔNp63α expression obtained 
by doxycycline 24h treatment (4μg/ml), SaOs-2 
cells were collected and fixed in 37% formaldehyde. 
Sonication was used to shear the chromatin, followed 
by immunoprecipitation with or without 10μl of anti-
HA antibody (Covance) for 2h using ChIP assay kit 
(Invitrogen). For the PCR we used the following 
primers: MMP13 +GCACCTCCAAGTCATCAAGC, 
_TGTGGGAAGAAGCAGAGAGTAG; MDM2 
+ GGTTGACTCAGCTTTTCCTCTTG, _ 
GGAAAATGCATGGTTTAAATAGCC.
Bioinformatics analyses
Gene expression datasets GSE31210, GSE2034, 
GSE30929 were downloaded from the GEO omnibus 
repository. Gene expression rank reflects relative mRNA 
expression level and is more consistent as it requires 
no normalization and thus introduces no normalization 
bias. Gene expression values were transformed into rank 
expression values on the scale from 100 to 0. Rank value 
55 means 55 per cent of probes in the sample have lower 
measured expression values. We use Pearson coefficient 
as a measure of correlation between expression profiles. 
Our primary aim is to divide samples in the dataset in two 
cohorts so that to maximize positive correlation between 
expression profiles of p63 and MMP13 in cohort 1 and to 
minimize positive correlation in cohort 2.  We start with 
all samples in cohort 1 and no samples in cohort 2. We 
compute correlation between p63 and MMP13 expression 
profiles in cohort 1 as well as compute the changes in 
correlation if one sample from the cohort would be 
removed. The sample with maximal effect on correlation 
(maximal increase in positive correlation) is moved from 
cohort 1 to cohort 2. The same procedure is repeated until 
there would be no one sample which could be removed 
from cohort 1, so to increase positive correlation between 
p63 and MMP13. The separation of patients into “cohort 
1” and “cohort 2” along with survival information is then 
used to find any statistical differences in survival outcome. 
The R statistical package is used to perform survival 
analyses and to draw KMplots.
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